Congress moves to cap drug prices at international levels—pharma stocks tumble
H.R. 3375 — Fair Prescription Drug Prices for Americans Act · Filed by Jefferson Van Drew (R-NJ) · Introduced May 13, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill caps U.S. prescription drug prices at the average price charged in Canada, France, Germany, Italy, Japan, and the United Kingdom. Manufacturers must report their prices annually, and those charging more than the international average face civil penalties equal to 10 times the price difference per unit sold. The goal is to lower drug costs for American patients by tying them to what other wealthy nations pay.
Why we flagged it
The bill's core mechanism is a price cap enforced through international reference pricing—tying U.S. drug prices to a basket of six wealthy nations and penalizing manufacturers who exceed that average. This is a direct regulatory intervention in pharmaceutical pricing, not a subsidy, tax break, or market-neutral measure.
What the text implies
- Manufacturers may respond by raising prices in reference countries (Canada, UK, etc.) to increase the 'average,' effectively shifting the burden to those nations' healthcare systems and potentially triggering retaliatory policy responses.
- The bill does not address biosimilar or generic drug pricing separately, potentially creating unintended incentives around market segmentation or product reformulation to avoid the cap.
The full analysis lists 5 implications of this text.
Who stands to gain
patients and consumers (lower out-of-pocket drug costs); health insurers and pharmacy benefit managers (lower claims costs); government health programs (Medicare, Medicaid lower drug spending)